Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Pharma
FDA challenges broad use of PD-1 drugs in stomach cancer
The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu
Sep 24, 2024 2:30pm
ESMO: BMS moves Opdualag into phase 3 trials in 1L NSCLC
Sep 14, 2024 2:40am
EQT leads $102M investment for radiopharma manufacturer PanTera
Sep 11, 2024 11:10am
BMS staffers start pedaling against cancer in fundraising push
Sep 9, 2024 11:21am
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
On 2nd glance, analyst reverses rosy view on IRA cuts
Aug 19, 2024 5:21pm
135d.jpg?VersionId=PWzPEw23obHNs4QJQDrTrwcviLT5dHcq)